Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 5Thoracic 4Genitourinary 2Gastrointestinal 2Dermatologic 2Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 607Lung Neoplasms 190Mesothelioma, Malignant 46Adenocarcinoma of Lung 42Mesothelioma 40Neoplasms 31Neoplasm Metastasis 28Carcinoma 18Colorectal Neoplasms 16Small Cell Lung Carcinoma 14Parkinson Disease 4, Autosomal Dominant Lewy Body 14NSCLC 14Adenocarcinoma 11Melanoma 10Lung Diseases 10Brain Neoplasms 10Adenocarcinoma, Bronchiolo-Alveolar 9Thoracic Neoplasms 8Non-squamous Non-small Cell Lung Cancer 8Carcinoma, Bronchogenic 8Respiratory Tract Neoplasms 7Non-Squamous Non-Small Cell Lung Cancer 7Neoplasms by Site 7Bronchial Neoplasms 7Respiratory Tract Diseases 6Ovarian Neoplasms 6Neoplasms by Histologic Type 6Meningeal Carcinomatosis 6Squamous Cell Carcinoma of Head and Neck 5Solitary Fibrous Tumor, Pleural 5

Interventions

pembrolizumab 48Nivolumab 22Cyclophosphamide 10Carboplatin 10spartalizumab 8atezolizumab 7Gemcitabine 7130-nm albumin-bound paclitaxel 7fludarabine 6Cisplatin 6Ipilimumab 5durvalumab 4budigalimab 4avelumab 4Pemetrexed 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Leucovorin 4Irinotecan 4Interleukin-2 4Immune Checkpoint Inhibitors 4Docetaxel 4Bevacizumab 4cemiplimab 3cabozantinib 3aldesleukin 3Standard of Care 3Specimen Handling 3Oxaliplatin 3Fluorouracil 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Pemetrexed × Thoracic × Clear all
NCT03396445 2025-11-05

MK-5890-001

Merck Sharp & Dohme LLC

Phase 1 Completed
182 enrolled 36 charts
BreastThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03267316 2024-08-22

CANFOUR

Cantargia AB

Phase 1/2 Completed
167 enrolled
BreastGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT02983045 2023-03-13

PIVOT-02

Nektar Therapeutics

Phase 1/2 Completed
557 enrolled 22 charts
BreastDermatologicGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡